These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Pergolide in Parkinson's disease: time for a change? Grosset KA; Grosset DG Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636 [No Abstract] [Full Text] [Related]
23. [Multiple latency test in a patient with episodes of sleep induced by pergolide]. Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281 [TBL] [Abstract][Full Text] [Related]
24. Pergolide and lisuride in advanced Parkinson's disease. Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627 [TBL] [Abstract][Full Text] [Related]
25. Pergolide in the treatment of Parkinson's disease. Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628 [No Abstract] [Full Text] [Related]
26. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide. Chung EJ; Yoon WT; Kim JY; Lee WY Mov Disord; 2006 Apr; 21(4):586-7. PubMed ID: 16482572 [No Abstract] [Full Text] [Related]
27. [Pergolide mesylate in the treatment of Parkinson's disease resistant to other treatments. First Italian experience]. Pezzoli G; Zecchinelli A; Mariani C; Reganati P; Scarlato G Clin Ter; 1991 Jan; 136(1):39-45. PubMed ID: 1826872 [TBL] [Abstract][Full Text] [Related]
28. Levodopa in the treatment of Parkinson's disease: current controversies. Gerlach M; Reichmann H; Riederer P Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130 [No Abstract] [Full Text] [Related]
29. [Isolated pulmonary hypertension and pergolide]. Evrard F; Dupuis M; Muller T; Jacquerye P Rev Neurol (Paris); 2008 Mar; 164(3):278-9. PubMed ID: 18405780 [TBL] [Abstract][Full Text] [Related]
30. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study. Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905 [TBL] [Abstract][Full Text] [Related]
31. Pergolide-induced pleuropulmonary fibrosis. Bleumink GS; van der Molen-Eijgenraam M; Strijbos JH; Sanwikarja S; van Puijenbroek EP; Stricker BH Clin Neuropharmacol; 2002; 25(5):290-3. PubMed ID: 12410064 [TBL] [Abstract][Full Text] [Related]
32. Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease. Bianchi M; Castiglioni MG Clin Neuropharmacol; 2005; 28(5):245-6. PubMed ID: 16239767 [TBL] [Abstract][Full Text] [Related]
33. The variability of levodopa response in Parkinson's disease: is sensitization reversible? Jabre MG; Bejjani BP Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452 [No Abstract] [Full Text] [Related]
34. [Sleep attacks and pergolide mesylate]. García Ruiz PJ; Hernández J; Cantarero S; Fanjul S Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938 [No Abstract] [Full Text] [Related]
36. The video images of sleep attacks in Parkinson's disease. Hirayama M; Nakamura T; Hori N; Koike Y; Sobue G Mov Disord; 2008 Jan; 23(2):288-90. PubMed ID: 18044704 [TBL] [Abstract][Full Text] [Related]
37. Reversible Pisa syndrome in Parkinson's disease during treatment with pergolide: a case report. Cannas A; Solla P; Floris G; Borghero G; Tacconi P; Spissu A Clin Neuropharmacol; 2005; 28(5):252. PubMed ID: 16239770 [No Abstract] [Full Text] [Related]